Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.

Lipinski MJ, Lee RC, Gaglia MA Jr, Torguson R, Garcia-Garcia HM, Pichard AD, Satler LF, Waksman R.

Cardiovasc Revasc Med. 2016 Dec;17(8):535-545. doi: 10.1016/j.carrev.2016.09.011. Epub 2016 Sep 30. Review.

PMID:
27842901
2.

Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.

Jacobs I, Petersel D, Shane LG, Ng CK, Kirchhoff C, Finch G, Lula S.

BioDrugs. 2016 Dec;30(6):489-523. Review.

3.

Intra-arterial versus intravenous abciximab therapy for thromboembolic complications of neuroendovascular procedures: case review and meta-analysis.

Kansagra AP, McEachern JD, Madaelil TP, Wallace AN, Cross DT 3rd, Moran CJ, Derdeyn CP.

J Neurointerv Surg. 2017 Feb;9(2):131-136. doi: 10.1136/neurintsurg-2016-012587. Epub 2016 Aug 18.

PMID:
27540089
4.

Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.

Su Q, Nyi TS, Li L.

Cochrane Database Syst Rev. 2015 May 18;(5):CD009503. doi: 10.1002/14651858.CD009503.pub3. Review.

PMID:
25985145
5.

Combination therapy of intravenous glycoprotein IIB/IIIA inhibitors and tissue plasminogen activator for acute ischemic stroke.

Dubey D, Banerjee C, Sawhney A, Sharma A, Alberts MJ.

Neurol India. 2014 Nov-Dec;62(6):631-4. doi: 10.4103/0028-3886.149385.

6.

Rescue treatment of thromboembolic complications during endovascular treatment of cerebral aneurysms: a meta-analysis.

Brinjikji W, Morales-Valero SF, Murad MH, Cloft HJ, Kallmes DF.

AJNR Am J Neuroradiol. 2015 Jan;36(1):121-5. doi: 10.3174/ajnr.A4066. Epub 2014 Jul 31.

7.

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives.

Dziewierz A, Rakowski T, Dudek D.

Ther Clin Risk Manag. 2014 Jul 18;10:567-76. doi: 10.2147/TCRM.S50002. eCollection 2014. Review.

8.

Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.

Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I.

Cochrane Database Syst Rev. 2014 Mar 8;(3):CD005208. doi: 10.1002/14651858.CD005208.pub3. Review.

PMID:
24609741
9.

Systematic evaluation of evidence on veterinary viscoelastic testing part 5: Nonstandard assays.

Brainard BM, Goggs R, Mendez-Angulo JL, Mudge MC, Ralph AG, Wiinberg B.

J Vet Emerg Crit Care (San Antonio). 2014 Jan-Feb;24(1):57-62. doi: 10.1111/vec.12146. Epub 2014 Jan 10.

PMID:
24410835
10.

Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.

Serebruany VL, Sibbing D, DiNicolantonio JJ.

Cardiology. 2014;127(1):20-4. doi: 10.1159/000354876. Epub 2013 Oct 26. Review.

PMID:
24192670
11.

Recanalization of acute carotid stent occlusion using Penumbra 4Max aspiration catheter: technical report and review of rescue strategies for acute carotid stent occlusion.

Munich S, Moftakhar R, Lopes D.

J Neurointerv Surg. 2014 Oct;6(8):e42. doi: 10.1136/neurintsurg-2013-010706.rep. Epub 2013 Oct 22. Review.

PMID:
24151116
12.

A review of intracoronary abciximab in percutaneous coronary interventions--where are we now and where do we go from here?

Sharma S, Bhalla K, Singh S.

Recent Pat Cardiovasc Drug Discov. 2013 Dec;8(3):192-6. Review.

PMID:
23957238
13.

Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis.

Wang JN, Diao S, Tang YJ, Hou AJ, Yuan HB, Zheng Y, Zhou YH.

PLoS One. 2013;8(2):e58077. doi: 10.1371/journal.pone.0058077. Epub 2013 Feb 28.

14.

The bivalirudin paradox: high evidence, low use.

De Servi S, Mariani G, Mariani M, D'Urbano M.

J Cardiovasc Med (Hagerstown). 2013 May;14(5):334-41. doi: 10.2459/JCM.0b013e32835f1915. Review.

PMID:
23442811
15.

Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials.

De Rosa S, Caiazzo G, Torella D, Indolfi C.

Int J Cardiol. 2013 Sep 30;168(2):1298-305. doi: 10.1016/j.ijcard.2012.12.003. Epub 2012 Dec 27.

PMID:
23273690
16.

A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Arnold DM, Kukaswadia S, Nazi I, Esmail A, Dewar L, Smith JW, Warkentin TE, Kelton JG.

J Thromb Haemost. 2013 Jan;11(1):169-76. doi: 10.1111/jth.12052. Review.

17.

[Primary coronary angioplasty for myocardial infarction--the view of the cardiologic surgeon].

Tabone X.

Ann Cardiol Angeiol (Paris). 2012 Nov;61(5):352-6. doi: 10.1016/j.ancard.2012.09.001. Epub 2012 Sep 23. French.

PMID:
23098611
18.

Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.

Robertson L, Ghouri MA, Kovacs F.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002071. doi: 10.1002/14651858.CD002071.pub3. Review.

PMID:
22895926
19.

Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.

Xu Q, Yin J, Si LY.

Int J Cardiol. 2013 Jan 20;162(3):210-9. doi: 10.1016/j.ijcard.2012.06.001. Epub 2012 Jul 4.

PMID:
22769575
20.

Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świątkiewicz I, Bliden KP, Gurbel PA.

Cardiol J. 2012;19(3):230-42. Review.

Supplemental Content

Loading ...
Support Center